At Mtech Access we create bespoke digital value communication tools to support our Pharma and Medtech clients’ market access and customer engagement strategies. Here we answer some of the questions...
Read More
Our experts in health economics, value communication, design and digital discussed how to craft digital payer value communication tools to meet the needs of internal stakeholders, including market access teams...
Read More
The National Institute for Health and Care Excellence (NICE) has published updated manuals for methods, processes and topic selection for Health Technology Assessments (HTA). This includes changes to how NICE...
Read More
In this webinar, we explored the challenges facing orphan medicines and other innovative rare disease treatments looking to achieve market access in Europe. Orphan medicines and rare disease treatments are...
Read More
On World Evidence-Based Healthcare Day (20th October 2021), Shona Lang (Senior Consultant -Evidence Synthesis), Stephanie Swift (Consultant - Evidence Synthesis) and Calum Jones (Consultant Health Economist) explore the role of...
Read More
Are you looking to launch a new medical technology, medical or diagnostic device in the UK, Europe or North America? Would you like to know how health economic modelling could...
Read More
Challenges for orphan medicines entering the European market – Part 3: Economic evidence development
In this four-part series, we explore the various challenges facing orphan medicines entering the European market and suggest solutions that can help improve patient access. In Part 3 of the...
Read More
Calum Jones, Consultant Health Economist at Mtech Access, shares his passion for helping MedTech firms build health economic models that help their innovative new technologies reach patients. Tell us about...
Read More
We are delighted to bring you our Pharma Market Access Insights Podcast. In this podcast we will offer insights and thought leadership from the market access and HEOR experts at Mtech...
Read More
Partitioned survival analysis (PartSA) is currently the most commonly used modelling approach within HTA (health technology assessment) for advanced or metastatic cancers. However, until recently, there was no formal documentation...
Read More